ArticleBMC cancer2026
Definitive carbon ion radiotherapy for thoracic bone and soft tissue sarcoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThoracic bone and soft tissue sarcoma (BSTS) represents a rare malignancy. For patients with medically inoperable BSTS, radiotherapy (RT) is a recommended treatment modality. Carbon ion radiotherapy (CIRT) has shown superior efficacy compared to photon-based RT. However, data on the use of CIRT for thoracic BSTS remain scarce. This study aimed to evaluate the clinical outcomes and toxicity profile of CIRT in patients with thoracic BSTS.
methodsThe inclusion criteria were as follows: 1) ≥ 14 years old; 2) primary or metastatic BSTS in chest area, with histologically confirmed primary tumor; 3) with visible lesion; 4) definitive CIRT intent; and 5) had at least one follow-up, and the time between follow-up and the first fraction of CIRT was longer than 1 month. The prescribed CIRT doses ranged from 59.5 to 80 Gy (RBE) delivered in 10-23 fractions. Treatment-related toxicities were assessed using the Common Terminology Criteria for Adverse Events Version 4.03, while tumor response was evaluated according to the Response Evaluation Criteria in Solid Tumors Version 1.1. Local control (LC), progression-free survival (PFS), and overall survival (OS) rates were estimated using the Kaplan-Meier method. Subgroup analyses were performed using the Log-rank test.
resultsA total of 33 patients with 35 lesions were included in the study. The median age of the cohort was 56 years (range: 22-86 years), with a median follow-up duration of 42.1 months (range: 3.8-100.6 months). The 3-year LC rates for the entire cohort were 85.2%. There was no statistically significant difference in LC when categorized by median tumor volume and biological effective dose. The use of simultaneous integrated boost technology appears to improve the LC. Among patients with primary thoracic BSTS, the 3-year LC, PFS， and OS rates were 84%, 54.8%， and 76.7%, respectively. Patients with postoperative recurrence (PORC) demonstrated significantly inferior PFS and OS. Except one case of grade 3 chest wall pain and 1 brachial plexopathy, no grade ≥ 3 toxicities were observed.
conclusionsCIRT is safe and effective in the management of thoracic BSTS. Further studies with more cases and longer observation periods are warranted.
trial registrationRetrospectively registered on 13th February, 2026; ChiCTR2600118943; Chinese Clinical Trial Registry; https://www.chictr.org.cn/bin/project/edit?pid=308155 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.